Medibact GuidesShop at Medibact

Stacking Module

5-Amino-1MQ Stacking Module

5-Amino-1MQ is an NNMT inhibitor and, like SLU-PP-332, a small molecule rather than a peptide. Its stacking module carries an additional warning that applies to almost nothing else here: specific-sounding human pharmacokinetic figures circulate for it that could not be verified in any peer-reviewed source.

5-Amino-1MQ Guide at Medibact5-Amino-1MQ calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking 5-Amino-1MQ

  • 5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide. Its predominant reported route is oral capsule or powder, not injection.
  • Efficacy data are mouse-only. A 2021 peer-reviewed review states explicitly that no NNMT-targeted clinical trials have been reported.
  • Specific half-life and oral-bioavailability figures attributed to a 'University of Vienna human PK study' circulate on commercial sites and could not be located in PubMed, PMC or any peer-reviewed source. Treat them as marketing.
  • No controlled trial has studied it combined with anything.

Combinations in detail

Metabolic / longevity stack

5-Amino-1MQ + MOTS-c
Why it is proposed
NNMT inhibition and AMPK activation are different metabolic mechanisms, so the pairing is not redundant on mechanism.
What is reported in practice
Reported concurrently; note the route difference — 5-Amino-1MQ predominantly oral, MOTS-c injected.
Cautions specific to this combination
MOTS-c has thin human data and 5-Amino-1MQ has effectively none. The pairing's confident framing online is not supported.

Body Recomposition Stack

5-Amino-1MQ + SLU-PP-332
Why it is proposed
Two metabolic small molecules with different targets, both discussed orally.
What is reported in practice
Reported together in body-composition discussion.
Cautions specific to this combination
Both are preclinical-only. This is the least-evidenced pairing in the metabolic group.

What to avoid, and why

  • Citing the unverified 'University of Vienna' pharmacokinetic figures — they contradict the peer-reviewed statement that no NNMT clinical trials have been reported.
  • Forcing it into an injection protocol; the reported predominant route is oral, and reconstitution examples for it should be read as concentration math rather than route guidance.
  • Treating mouse efficacy data as translatable to human dosing.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.